Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
Subscribe To Our Newsletter & Stay Updated
